scholarly journals Pulmonary sarcoidosis presenting as a solitary nodule mimicking lung cancer

2021 ◽  
Vol 9 (6) ◽  
Author(s):  
Tomoyo Taketa ◽  
Takahito Nakamura
Author(s):  
Tomoyo Taketa ◽  
Takahito Nakamura

Sarcoidosis shows various clinical and radiologic manifestations. Nodular sarcoidosis is an uncommon form of pulmonary sarcoidosis. Cases presenting as solid nodules are especially rare. We herein present a case of nodular sarcoidosis with a solid nodule that was suspected to be lung cancer.


2010 ◽  
Vol 49 (18) ◽  
pp. 1997-2001 ◽  
Author(s):  
Hirokazu Tokuyasu ◽  
Hiroki Izumi ◽  
Natsuko Mukai ◽  
Kenichi Takeda ◽  
Yasuto Sakaguchi ◽  
...  

Haigan ◽  
2000 ◽  
Vol 40 (1) ◽  
pp. 51-55
Author(s):  
Kazuhiro Sakamoto ◽  
Masahiro Kase ◽  
Tatsushi Yamagata ◽  
Hideyuki Sato ◽  
Koshiro Watanabe

Lung Cancer ◽  
2012 ◽  
Vol 77 ◽  
pp. S42-S43
Author(s):  
Svetlana Žunić ◽  
Snežana Žunić-Božinovski

Haigan ◽  
1987 ◽  
Vol 27 (3) ◽  
pp. 301-306 ◽  
Author(s):  
Mayumi Sasagawa ◽  
Kozo Tawaraya ◽  
Akihiko Nagai ◽  
Satoru Kioi ◽  
Masaaki Arakawa ◽  
...  

1999 ◽  
Vol 13 (5) ◽  
pp. 705-709
Author(s):  
Kiyotomi Maruyama ◽  
Yoshihiro Minamiya ◽  
Hideki Kawai ◽  
Jun-ichi Ogawa

2017 ◽  
Vol 10 (3) ◽  
pp. 1070-1075 ◽  
Author(s):  
Ghina Fakhri ◽  
Reem Akel ◽  
Ziad Salem ◽  
Ayman Tawil ◽  
Arafat Tfayli

Background: Pembrolizumab is a humanized monoclonal antibody which serves to enhance the antitumor immune response by targeting programmed cell death 1 receptor. The use of pembrolizumab plus carboplatin/pemetrexed combination therapy results in improvement in overall survival and progression-free survival rates for non-small cell lung cancer (NSCLC) patients as compared to chemotherapy alone. However, numerous immune-mediated toxicities of pembrolizumab have been reported. Case Presentation: We report the case of a 74-year-old male patient diagnosed with stage IIIA programmed death-ligand 1-positive non-small cell lung adenocarcinoma treated with 4 cycles of carboplatin/pemetrexed plus pembrolizumab combination therapy followed by 2 cycles of pembrolizumab treatment. Follow-up PET-CT scanning showed a very good response at the level of the tumor but new-onset activity in bilateral hilar and mediastinal lymph nodes. Biopsy of these lymph nodes revealed a benign pathology with noncaseating granulomas consistent with immune-mediated sarcoidosis. Conclusion: The pathogenesis of immunotherapy-induced sarcoidosis is not yet known but has been reported in different cancers and using different checkpoint inhibitors. To our knowledge, this case is the first in the literature displaying pulmonary sarcoidosis in a patient with NSCLC 4 months after having initiated chemotherapy plus pembrolizumab combination therapy.


2017 ◽  
Vol 56 (15) ◽  
pp. 1957-1960 ◽  
Author(s):  
Yuki Iijima ◽  
Yukihiko Sugiyama ◽  
Michiru Sawahata ◽  
Masayuki Nakayama ◽  
Masashi Bando

Haigan ◽  
1993 ◽  
Vol 33 (6) ◽  
pp. 971-976
Author(s):  
Takeshi Isobe ◽  
Takafumi Tsuya ◽  
Kenji Niitani ◽  
Yasuhiro Yoshida ◽  
Kenji Hasegawa ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document